Urologix to Host Its Fiscal Year 2014 Second Quarter Conference Call

Urologix to Host Its Fiscal Year 2014 Second Quarter Conference Call

MINNEAPOLIS, Jan. 30, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB:ULGX)
will host a conference call to present fiscal year 2014 second quarter results
on Tuesday, February 4, 2014 at 4:00 p.m. CT, following the Company's
post-market press release on the same day. On the day of the call, please dial
1-800-688-0836 and enter the Participant Passcode 89504173 at least 10 minutes
prior to the call. The conference call will be broadcast live over the
Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host
the call.

Webcast listeners should log on at least 10 minutes prior to the scheduled
start time of the call to register and download or install any required audio
software. A replay of the call will be available until February 11, 2014 at
11:59 p.m. CT. To listen to the replay, please dial 1-888-286-8010 and enter
the Participant Passcode 46431357.

The webcast is also being distributed over CCBN's Investor Distribution
Network to both institutional and individual investors. Individual investors
can listen to the call through CCBN's individual investor center at
www.companyboardroom.com or by visiting any of the investor sites in CCBN's
Individual Investor Network. Institutional investors can access the call via
CCBN's password-protected event management site, StreetEvents
(www.streetevents.com).

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and
distributes minimally invasive medical products for the treatment of
obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix'
Cooled ThermoTherapy™ produces targeted microwave energy combined with a
unique cooling mechanism to protect healthy tissue and enhance patient
comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and
Targis® Control Units and the CTC Advance® and Targis® catheter families. The
Prostiva® RF Therapy System delivers radio frequency energy directly into the
prostate destroying prostate tissue, reducing constriction of the urethra, and
thereby relieving BPH voiding symptoms. Both of these products provide safe,
effective and lasting relief of the symptoms and obstruction due to BPH.
Prostiva® is a registered trademark of Medtronic, Inc., used under license.
All other trademarks are the property of Urologix.

CONTACT: Brian Smrdel
         Chief Financial Officer
         Urologix, Inc.
         763-475-1400
         bsmrdel@urologix.com
 
Press spacebar to pause and continue. Press esc to stop.